Download our app Order a test

Helping you to make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with your healthcare provider to deliver a range of personalised tests so together you can choose the best treatment.

More patient information

Introducing
Cancer A-Z

Our brand new patient-focused app

Find out more

Download now

Common requests

Find answers to some of your most frequently asked questions

Medical Professionals

Do I need to sign any paperwork?In which countries are RGCC tests approved for use?How many types of cancer are tested when RGCC says “all types of cancer”?Can RGCC test for BRAF drugs?

Patient Information

How long do test results take to process?Are your testing methods accredited internationally?

Cancer tests

New methods and reliable tests to help deliver personalised treatment

RGCC CAMBISeq®

RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer.  The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their […]

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]

View test

Immune-Frame

Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about […]

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]

View test

ChemoSNiP

ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments […]

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of […]

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests […]

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments […]

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]

View test

Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

13th Day of Life Sciences

9th June 2022
ZHAW Life Sciences and Facility Management, Grüentalstrasse 14, 8820 Wädenswil(PDF 3,0 MB)

We are delighted to be one of the main sponsors at the 13th Day of Life Sciences on 9th June 2022. Register for the symposium ‘Competencies in Drug Discovery’ by 7th June, we look forward to seeing you there! Day of Life Sciences | ZHAW Life Sciences and Facility Management

Read more

Genetic mutation could hold the key to new breast cancer treatments

Posted: 3rd May 2022
Categories: Industry news

Scientists have identified a mutated gene that causes breast cancer to become more aggressive and spread to other parts of the body in up to 30% of patients. The discovery provides exciting new avenues to develop new treatments for breast cancer, including more effective personalised approaches. Hormone therapy effectively treats around two-thirds of breast cancers, […]

Read more

New immunotherapy target for colon cancer found

Posted: 8th April 2022
Categories: Industry news

German scientists have identified the proteins inside colon cancer cells that trick the immune system from seeing them as a threat. But, in lab tests, once researchers blocked the signals from the cells, the immune systems began to attack them. The insight could help scientists develop new and highly targeted immunotherapies for one of the […]

Read more

New tumour biobank powers personalised cancer treatments

Posted: 22nd March 2022
Categories: Industry news

Scientists have discovered new and more effective ways of growing breast cancer tumours that could accelerate research and the development of new treatments. Instead of transplanting human tumours into mice, they’ve developed a bank of “human patient-derived xenografts (PDXs)” that can be used to screen drugs. Used alongside personalised genetic tests could improve cancer treatment […]

Read more

SOTs effective at treating cancer in 77% of patients

Posted: 9th March 2022
Categories: RGCC news

Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies.  Supportive oligonucleotide therapy is an advanced, […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more